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Diabetes and risk of peripheral artery
disease in patients undergoing first-time
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2012 – a nationwide study
Sadaf Kamil1,2,3* , Thomas S. G. Sehested2, Nicholas Carlson4,5, Kim Houlind6,7, Jens F. Lassen8, Casper N. Bang9,
Helena Dominguez2,3, Christian T. Pedersen10 and Gunnar H. Gislason1,5
Abstract
Background: The risk of peripheral artery disease (PAD) in patients with diabetes mellitus (DM) and coronary artery
disease (CAD) is an important and inadequately addressed issue. Our aim is to examine the impact of DM on risk of
PAD in patients with different degrees of CAD characterized by coronary angiography (CAG).
Methods: Using nationwide registers we identified all patients aged ≥18 years, undergoing first time CAG between
2000 and 2012. Patients were categorized into DM/Non-DM group, and further classified into categories according
to the degree of CAD i.e., no-vessel disease, single-vessel disease, double-vessel disease, triple-vessel disease, and
diffuse disease. Risk of PAD was estimated by 5-year cumulative-incidence and adjusted multivariable Cox-regression
models.
Results: We identified 116,491 patients undergoing first-time CAG. Among these, a total of 23.969 (20.58%) had DM.
Cumulative-incidence of PAD among DM patients vs. non-DM were 8.8% vs. 4.9% for no-vessel disease, 8.2% vs. 4.8%
for single-vessel disease, 10.2% vs. 6.0% for double-vessel disease, 13.0% vs. 8.4% for triple-vessel disease, and 6.8% vs.
6.1% for diffuse disease, respectively. For all patients with DM, the cox-regression analysis yielded significantly higher
hazards of PAD compared with non-DM patients with HR 1.70 (no-vessel disease), 1.96 (single-vessel disease), 2.35
(double-vessel disease), 2.87 (triple-vessel disease), and 1.46 (diffuse disease), respectively (interaction-p 0.042).
Conclusion: DM appears to be associated with increased risk of PAD in patients with and without established CAD,
with increasing risk in more extensive CAD. This observation indicates awareness on PAD risk in patients with DM,
especially among patients with advanced CAD.
Keywords: Type 2 diabetes mellitus, Peripheral artery disease, Coronary artery disease, Atherosclerosis
Background
Peripheral artery disease (PAD) is characterized as nar-
rowing of the arteries in the upper and lower extremities
arteries [1]. Atherosclerosis is recognized as the most
direct and important cause of PAD, leading to acute or
chronic limb ischemia [2]. PAD is known to be one of
the major complications of diabetes mellitus (DM) [3–6].
The Framingham heart study indicates that 20% of symp-
tomatic PAD patients presents DM [7]. However, as PAD
is mostly asymptomatic, a higher risk of DM in this group
of patients is assumed [8, 9].
Several large population-based studies have indicated
that DM is associated with a two- to four-fold increase
in development of PAD compared to non-diabetic
patients, moreover studies have shown a three- to four-
fold increased risk of mortality in patients with DM and
PAD compared to healthy individuals [10–13]. Addition-
ally, patients with concomitant PAD and DM experience
reduced quality of life and an increase in long-term
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disability and functional impairment [14, 15]. Screening
for PAD is therefore advocated in the international
guidelines [16]. Comparably, the European Association
for the Study of Diabetes recommends annual screening
in all patients regardless of risk factors [17]. Of note,
PAD is associated with substantial increased risk of fatal
and non-fatal cardiovascular and cerebrovascular events,
plausibly due to a greater degree of overall systemic ath-
erosclerosis [18, 19]. Thus, an early detection and timely
treatment of clinical risk factors may contribute in redu-
cing the prevalence and severity of PAD in patients with
DM and coronary artery disease (CAD).
Nevertheless, the association of PAD with respect to
the severity of cardiovascular calcification remains un-
tested, and the impact of DM on development of PAD
in patients with CAD needs further study. With the
present study, we aimed to investigate the association of
cardiovascular calcification with PAD in patients with
and without DM undergoing de novo coronary angiog-
raphy (CAG) in a real-world nationwide setting.
Methods
Study design and data sources
All Danish citizens have a unique and permanent civil
registration number that enables individual-level linkage
across all Danish nationwide registers [20–24]. In the
present study, patients were identified by using the
Danish Heart Registry (DHR), a clinical database con-
taining information on all patients referred for CAG
within the Danish healthcare system [25]. The Danish
National Patient Registry holds information on all in-
patient and out-patient treatments [recorded as Inter-
national Classification of Diseases (ICD) codes] nationwide
since 1978 and was used to retrieve information on comor-
bidities, prior to the CAG procedure date [20]. The Danish
Register of Medicinal Product Statistics (National Prescrip-
tion Register) holds information on all prescribed medicine
dispensed since 1995 according to The International Ana-
tomical Therapeutic Chemical (ATC) classification system
and was used to obtain data on concomitant pharmaco-
therapy. These Danish registers have previously been
shown to be complete and accurate [20, 21]. The present
study is conducted and reported in accordance with the
recommendation of Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) [20].
Inclusion criteria and classification of patients
This present study included all Danish citizens aged
≥18 years, undergoing first-time CAG over a period of
12 years spanning January 1, 2000 to December 31,
2012. Patients with more than one CAG within the
study period were only included at their first appear-
ance only. Moreover, the study subjects were censored
on death, migration, and at the end of study period
(December 31, 2012). The study population was then
segregated into patients with DM and patients without
DM (non-DM) with a further subdivision into five
categories of CAD i.e. no-vessel disease, single-vessel
disease, double-vessel disease, triple-vessel disease, and
diffuse disease. Obstructive coronary artery disease (i.e.
single-, double- or triple-vessel disease) was defined as
one or more epicardial coronary arteries with > 50%
angiographic lumen narrowing, whereas no-vessel disease
was defined as angiographic lumen narrowing (< 50%) in a
single coronary vessel. On the similar lines, patients regis-
tered with diffuse (coronary artery) disease includes those
with diffuse non-significant atherosclerosis in more than
one coronary artery or with non-obstructive (< 50%) lesions
in multiple coronary vessels. Of notice, the degree of vessel
disease was to the discretion of the invasive cardiologist.
Outcome
PAD was the outcome of interest and was defined as all
arterial diseases except the atherosclerotic disease of cor-
onary arteries, aorta, and intracranial arteries. ICD-10
diagnoses codes (DI170, DI73, DI74) were used to iden-
tify patients with PAD. Moreover, the diagnoses of PAD
registered in Danish National Patient Registry are vali-
dated with an over-all positive predictive value of 100%
(CI 92.9–100) [26]. Patients with a history of PAD (n =
7.342) at baseline were excluded from the study cohort
before the study start.
Pharmacotherapy and comorbidity
Baseline pharmacotherapy was defined by dispensed
prescriptions 180 days prior to CAG. Comorbidities
were established based on diagnostic codes recorded in
the National Patient Registry, including atrial fibrilla-
tion, hypertension, vascular disease, renal disease, and
thromboembolism. Hypertension was identified by
either a hospital diagnosis for hypertension, or concurrent
use of at least 2 of the following classes of antihypertensive
agents within a 3-month period: α-adrenergic blockers,
non-loop diuretics, vasodilators, β-blockers, calcium-
channel blockers, and renin-angiotensin system inhibitors.
DHR records information on DM status, body mass index
(BMI), and smoking status on all patients undergoing
CAG. To increase the sensitivity of the exposure group,
we defined DM by use of glucose-lowering agents and a
diagnosis of DM retrieved from DHR and National Pre-
scription Register, respectively. The respective ICD, ATC,
codes for all examined comorbidities and concomitant
medications are presented in Table 1.
Statistical analysis
Baseline characteristics were presented as medians, fre-
quencies and percentages. χ2-test was used to test the
difference between categorical variables and t-test or the
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Kruskal-Wallis test for differences between continuous
variables. The level of statistical significance was set as
p < 0.05. Risk of PAD in 5-years of follow-up, between
the respective subgroups were presented as cumulative
incidence curves with 95% confidence interval (CI)
using the Aalen-Johansen method. Risk-time was consti-
tuted of time since CAG procedure date until an outcome
of PAD occurred. Multivariable Cox proportional-hazard
models adjusted for sex, age, smoking status, BMI, hyper-
tension, and concomitant medication (beta-blockers, vita-
min K antagonist, platelet inhibitors, acetylsalicylic acid,
and cholesterol lowering drugs), were used to estimate
hazard ratios (HR) and confidence intervals of PAD
between subgroups of patients with and without DM.
Patients with no-DM and no-vessel disease were used as
references.
All statistical analyses were performed with SAS statis-
tical software version 9.4 (SAS Institute Inc., Cary, North
Carolina, USA), R statistics (R Core Team, 2016), and
Stata software version 14 (Statacorp, College St., Texas,
USA).
Results
A total of 116,491 patients underwent first-time CAG
between January 1, 2000 and December 31, 2012. Pa-
tients with previous known PAD by the start of the
study (n = 7.342) were excluded. A total of 23,969
(20.58%) were identified with DM. Mean age was 64.31
[IQR 56–73 years], and 63.67% of the identified patients
were male. A flowchart of the study population is illus-
trated in Fig. 1, and baseline characteristics stratified by
the degree of CAD among patients with and without
DM are presented in Table 2.
Table 3 demonstrates number of patients (given in
percentages) with DM and non-DM in categories of
CAD showing a higher percentage of double, triple, and
diffuse-vessel disease among patients with DM, com-
pared to non-DM patients.
The primary endpoint i.e. PAD was diagnosed in 4.737
patients (4.07%) in a 5-year follow-up period with a
higher percentage among patients with DM (6.15%)
compared to non-DM patients (3.53%).
The 5-year cumulative incidence of PAD among DM
patients were 8.8, 8.2, 10.2, 13.0, and 6.8% in no-vessel dis-
ease, single-vessel disease, double-vessel disease, triple-
vessel disease, and diffuse disease, respectively. Whereas,
the corresponding cumulative incidence of PAD among pa-
tients with non-DM were 4.9, 4.8, 6.0, 8.4, and 6.1% in no-
vessel disease, single-vessel disease, double-vessel disease,
triple-vessel disease, diffuse disease, respectively (Fig. 2).
Correspondingly, the age- and sex-adjusted cox regres-
sion models yielded increased hazards of PAD among
DM patients with HR 1.73 (1.59–1.87), 1.91 (1.63–2.24),
2.37 (1.99–2.83), 2.94 (2.57–3.37), and 1.59 (1.28–1.97)
in no-vessel disease, single-vessel disease, double-vessel
disease, triple-vessel disease, and diffuse disease, respect-
ively. On the contrary, hazards of PAD in non-DM patients
were comparably lower with HR 1.0, 1.12 (0.92–1.05), 1.30
(1.17–1.36), 1.77 (1.53–1.72), and 1.36 (0.92–1.06) in no-
vessel disease, single-vessel disease, double-vessel disease,
triple-vessel disease, diffuse disease, respectively. P for inter-
action between DM and degree of CAD, compared to non-
DM was 0.042. Furthermore, the fully adjusted HRs
remained significant, showing an increased risk of PAD in
patients with DM that appears to increase with the severity
of CAD (Table 4).
Discussion
In a nationwide register-based cohort study on all pa-
tients undergoing CAG, DM was observed to be inde-
pendently associated with increasing risk of PAD
dependent on severity of CAD. Moreover, the over-all
associated risk of PAD remained significantly increased
in patients with DM compared to non-DM patients.
PAD is defined as atherosclerosis of the lower extrem-
ity arteries and it is associated with increased risk of
lower extremity amputation and impaired life quality
[27]. Studies have linked this group of patients with a
higher risk of DM [8–10, 28]. DM-associated athero-
sclerosis affects all major vascular beds, including car-
diovascular system and arteries of the lower extremity
Table 1 Overview of ICD, and ATC codes for all examined
comorbidities and concomitant medications
Pharmacological Treatments ATC
Cholesterol-lowering drugs C10A
Acetylsalicylic acid B01AC06
Glucose-lowering agents A10
Vitamin K antagonists B01AA
Digoxin C01AA
Platelet inhibitors B01AC
Hypertension
Α-adrenergic blockers C02A, C02B, C02C, C02DA, C02L,
C03A, C03B, C03D, C03E, C03X,
C07C, C07D, C08G, C09BA, C09DA,
C09XA52, C02DB, C02DD, C02DG,
C07, C07F, C08, C09BB, C09.
Non-loop diuretics
Vasodilators
Β-blockers
Calcium channel blockers
Renin angiotension system
inhibitors
Comorbidity ICD-10
Vascular disease I21 to I22
Atrial fibrillation I48
Thromboembolism I26, I63, I64, I74, G458, G459
Hypertension I10 to I15
Renal Disease N03, N04, N17 to N19, R34, I12, I13
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and thereby contributes to cardiovascular disease burden
and mortality [29]. An estimated 15% of patients with
DM are reported to have PAD within 10 years after the
time they are diagnosed with DM, and the number in-
creases to 45% after 20 years [19]. PAD in patients with
DM causes long-term disability including ischemic ulcer
or gangrene, which ultimately may result in limb ampu-
tations [30]. The American Diabetes Association consen-
sus panel recommends screening for PAD in all DM
patients above the age of 50, or if they have risk factors
such as smoking, dyslipidemia, and hypertension [16].
Although some studies have addressed this subject,
results are based on limited data [18, 31, 32] and larger
population based studies are warranted. We, therefore,
used Danish national registers to examine the risk of
PAD in patients with DM compared to non-diabetics
and its relationship to CAD in a nationwide setting. The
results in the present study confirm previous observa-
tions of an augmented risk of developing PAD in pa-
tients with DM and CAD, compared to patients without
DM [31, 32]. Furthermore, this risk increases by the
severity of CAD in patients with and without DM. How-
ever, in our study patients with diffuse disease in DM
patients appears to have a lower cumulative incidence of
PAD compared to no-vessel disease (Fig. 2). As the
cumulative incidences of an event of interest are calcu-
lated in the presence of a competing risk (e.g. death),
this variance in diffuse disease group could be explained
by the substantial number of patients that die during the
follow-up without experiencing the study outcome.
Moreover, the HRs of PAD in patients with DM who
suffer diffuse disease compared to no-vessel disease are
not significantly different. Also, compared to diffuse and
obstructive coronary artery disease, the proportion of
patients with no-vessel disease was found to be higher in
patients with DM (54%) and non-DM (63%). The degree
of vessel disease recorded in DHR was subject to the dis-
cretion of the invasive cardiologist, which could result in
more patients with borderline angiographic lumen nar-
rowing (i.e. slightly higher than 50%) that are most likely
registered as no-vessel disease. Of notice, patients at risk
of developing CAD (including patients with DM) are
most likely to be referred at earlier course of their dis-
ease, which may also explain a higher proportion of
diffuse, no-vessel or single-vessel disease. Indeed, this
notion is supported by the results demonstrated by Da-
nish Health Authority (Sundhedsstyrelsen) and Danish
Heart Foundation (Hjerteforeningen) indicating an in-
creasing trend in number of coronary angioplasties per
million Danish inhabitants [33].
Fig. 1 Flowchart of selection of study population
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DM is characterized by hyperglycemia, insulin resist-
ance, and dyslipidemia that contribute to development
and progression of PAD, through pathophysiological
mechanisms (e.g. vascular inflammation, endothelial dys-
function, hemostasis dysregulation) similar to those in
CAD [12, 34]. Vascular inflammation is a risk marker of
atherothrombosis, and studies have shown that CAD pa-
tients with an additional diagnosis of PAD have higher
circulating levels of inflammatory biomarkers [9, 35]. In
view of that, the vascular inflammation caused by DM
may play a contributing role in development of PAD by
accelerating the disease process in patients with known
CAD [12]. In addition, choice of glucose-lowering agents
Fig. 2 Cumulative Incidence Curve and patients at risk within 5 years from coronary angiography stratified by degree of CAD in patients with DM
compared to non-DM patients. At risk table represents number of patients at risk of event at given time
Table 3 Percentages of CAD in patients with and without DM
Degree of CAD Non-DM DM
No vessel disease 61.52% 54.80%
Single vessel disease 14.73% 13.85%
Double vessel disease 6.93% 8.81%
Triple vessel disease 7.59% 12.50%
Diffuse vessel disease 9.23% 10.04%
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may have an important impact on the development of
atherosclerotic plaques [36]. Moreover, risk of develop-
ing PAD in patients with concurrent DM and advance
CAD also depend on interplay between factors such as
comorbidities, smoking, obesity, and reduced physical
activity [11]. These factors foster development of athero-
thrombosis and they are often present before the diagno-
sis of DM and worsen in line with the duration of DM
[37]. Moreover, due to the distal territory of vessel in-
volvement and its association with peripheral neur-
opathy, PAD is more commonly asymptomatic in
patients with DM and may present later at a more ad-
vanced stage [38]. Also, the lower resistance to infection
of this group dramatically increases their risk of amputa-
tion compared to non-diabetic patients with PAD [30].
Thus, an early detection and timely treatment of clinical
risk factors may contribute in reducing the prevalence
and severity of PAD in patients with DM and CAD.
Taken together, results from the present study add to
the existing evidence that patients with concurrent DM
and CAD may be at increased risk of developing PAD
and this risk appears to worsen in advance CAD. Clini-
cians should be aware and may want to consider screen-
ing and treatment at early stage to elicit the adverse
outcomes, specifically in high risk population of patients
with DM and CAD. Nevertheless, prospective studies
aimed to explore effects of such outcomes are required.
Strengths and limitations
Large number of unselected patients in a real-world
nationwide setting, completeness of follow-up, and use
of validated measures of exposure and outcome are
among the strengths of the present study. Furthermore,
healthcare in Denmark is equally accessible to all Danish
citizens minimizing confounding by variables associated
with social class. It is our opinion that this large-scale
nationwide study provides a reliable image of the CAG
population under investigation.
There are also several limitations in the study that
must be acknowledged. The observational nature of the
study only allows to establish association and does not
represent cause-and-effect relationships. Moreover, the
subpopulation was identified by using diagnosis from
registers along with data on claimed prescriptions.
Although the registration of data in Danish registers is
thought to be accurate, there might be some limitations
regarding the PAD diagnoses; especially as PAD is
underreported due to the often asymptomatic nature of
the disease. Also, development of neuropathy in patients
with DM often suppresses PAD symptoms leading to
late diagnosis of PAD. In opposite, patients with DM are
followed closely with regularly health checkups that
might lead to earlier detection of PAD. The registries
used in this study do not include information on glyco-
sylated hemoglobin levels and patients with DM man-
aged with diet alone or developing DM during the
follow up period were not identified. To address this
issue, we defined DM by use of glucose lowering agents
and the recorded diagnoses of DM in DHR and National
Prescription Register, respectively. Nevertheless, the re-
sults are only valid for patients with DM requiring
pharmacotherapy at the time of CAG. Moreover, DHR
lacked information on various clinical parameters in-
cluding thorough data on the luminal diameter and pre-
cise extent of coronary artery stenosis (in percentage).
Conclusion
In this observational nationwide study of patients under-
going CAG, DM was associated with increased risk of
PAD in patients with and without established CAD.
Additionally, we observed increasing risk of PAD with
more extensive CAD. Further studies are warranted to
support these findings.
Abbreviations
BMI: Body mass index; CAD: Coronary artery disease; CAG: Coronary
angiography; DM: Type 2 diabetes mellitus; HR: Hazard ratio; IR: Incidence
rate; PAD: Peripheral artery disease
Acknowledgements
Not applicable.
Authors’ contributions
SK and GG designed the study and performed statistical analyses. SK wrote
the initial draft of the paper. All authors (SK, TS, NC, KH, JFL, CNB, HD, CTP,
GG) contributed equally to interpretation of data, revised the paper for
important intellectual content and approved the final version of the paper.
Funding
The study was financially supported by “Herlev/Gentofte Intern Forskningspulje”.
The study sponsors had no influence on data collection, interpretation of data,
nor the final decision to submit the manuscript for publication.
Table 4 Hazard ratios and 95% confidence intervals of PAD in
patients with and without DM with respect to degree of CAD
along with individual covariates
Hazard Ratio 95% Confidence
Interval
P-Value
Non-DM
No-CAD (reference) 1.0 NA NA
Single-vessel disease 1.15 1.03–1.29 0.013
Double-vessel disease 1.37 1.18–1.58 < 0.001
Triple-vessel disease 1.82 1.61–2.05 < 0.001
Diffuse-vessel disease 1.33 1.16–1.52 < 0.001
DM
No-CAD 1.70 1.55–1.86 < 0.001
Single-vessel disease 1.96 1.67–2.31 < 0.001
Double-vessel disease 2.35 1.96–2.82 < 0.001
Triple-vessel disease 2.87 2.50–3.30 < 0.001
Diffuse-vessel disease 1.46 1.17–1.84 < 0.001
Kamil et al. BMC Cardiovascular Disorders          (2019) 19:234 Page 7 of 9
Availability of data and materials
The datasets generated and/or analysed during the current study are not
publicly available but are accessible on reasonable request and through
permission from DST (Danmark statistik).
Ethics approval and consent to participate
The study was approved by the Danish Data Protection Agency (ref. 2007-
58-0015, int. ref.: GEH-2014-018), and data were made available in a way that
individuals could not be identified. Approval from an ethics committee is
not required for retrospective register-based studies in Denmark.
The data that support the findings of this study are available from third party
(DST, Danmark Statistik) but restrictions apply to the availability of these data
and they are not publicly available. Data are only available upon reasonable
request and through permission from DST.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Cardiology, Copenhagen University Hospital Herlev-Gentofte,
Herlev and Gentofte Hospital, Kildegaardsvej 28, 2900 Hellerup, Denmark.
2Department of Cardiology, Bispebjerg-Frederiksberg University Hospital,
Copenhagen, Denmark. 3Department of Biomedical Sciences, University of
Copenhagen, Copenhagen, Denmark. 4Department of Nephrology,
Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 5The
Danish Heart Foundation, Copenhagen, Denmark. 6Department of Vascular
Surgery, Kolding Hospital, Kolding, Denmark. 7Department of Regional Health
Research, University of Southern Denmark, Odense, Denmark. 8Department
of Cardiology, Odense University Hospital, Odense, Denmark. 9Department of
Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen,
Denmark. 10Department of Cardiology, Nordsjaellands Hospital, Hilleroed,
Denmark.
Received: 26 March 2019 Accepted: 30 September 2019
References
1. Schorr EN, Treat-Jacobson D, Lindquist R. The relationship between
peripheral artery disease symptomatology and ischemia. Nurs Res. 2017;
66(5):378–87.
2. Ciocan RA, Bolboaca SD, Radulescu S, Stancu B, Ciocan A, Gherman CD.
Demographic and comorbidity pattern of patients with critical limb
ischemia. Folia Med. 2017;59(1):14–22.
3. Davidson MH. Cardiovascular risk factors in a patient with diabetes mellitus
and coronary artery disease: therapeutic approaches to improve outcomes:
perspectives of a preventive cardiologist. Am J Cardiol. 2012;110(9 Suppl):
43b–9b.
4. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al.
Mortality over a period of 10 years in patients with peripheral arterial
disease. N Engl J Med. 1992;326(6):381–6.
5. Inglis SC, Hermis A, Shehab S, Newton PJ, Lal S, Davidson PM. Peripheral
arterial disease and chronic heart failure: a dangerous mix. Heart Fail Rev.
2013;18(4):457–64.
6. Paraskevas KI, Mukherjee D, Whayne TF Jr. Peripheral arterial disease:
implications beyond the peripheral circulation. Angiology. 2013;64(8):569–71.
7. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes.
J Am Coll Cardiol. 2006;47(5):921–9.
8. Ali Z, Ahmed SM, Bhutto AR, Chaudhry A, Munir SM. Peripheral artery
disease in type II diabetes. J Coll Physicians Surg Pak. 2012;22(11):686–9.
9. Snell-Bergeon JK, Budoff MJ, Hokanson JE. Vascular calcification in diabetes:
mechanisms and implications. Curr Diab Rep. 2013;13(3):391–402.
10. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in
diabetes--a review. Diabet Med. 2010;27(1):4–14.
11. Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA,
et al. Associations between conventional cardiovascular risk factors and risk
of peripheral artery disease in men. JAMA. 2012;308(16):1660–7.
12. van Ark J, Moser J, Lexis CP, Bekkema F, Pop I, van der Horst IC, et al. Type 2
diabetes mellitus is associated with an imbalance in circulating endothelial and
smooth muscle progenitor cell numbers. Diabetologia. 2012;55(9):2501–12.
13. Mercer BN, Morais S, Cubbon RM, Kearney MT. Diabetes mellitus and the
heart. Int J Clin Pract. 2012;66(7):640–7.
14. Argyriou C, Saleptsis V, Koutsias S, Giannoukas AD. Peripheral arterial disease
is prevalent but underdiagnosed and undertreated in the primary care
setting in Central Greece. Angiology. 2013;64(2):119–24.
15. Faglia E. Characteristics of peripheral arterial disease and its relevance to the
diabetic population. Int J Low Extrem Wounds. 2011;10(3):152–66.
16. Bosevski M. Peripheral arterial disease and diabetes. Prilozi. 2012;33(1):65–78.
17. Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4–s36.
https://doi.org/10.2337/diacare.28.suppl_1.S4.
18. Sukhija R, Yalamanchili K, Aronow WS. Prevalence of left main coronary
artery disease, of three- or four-vessel coronary artery disease, and of
obstructive coronary artery disease in patients with and without peripheral
arterial disease undergoing coronary angiography for suspected coronary
artery disease. Am J Cardiol. 2003;92(3):304–5.
19. Yilmaz MB, Guray Y, Guray U, Biyikoglu SF, Tandogan I, Korkmaz S. Metabolic
syndrome increases the risk of significant coronary artery involvement in
patients with peripheral artery disease. Coron Artery Dis. 2006;17(6):529–32.
20. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register.
Scand J Public Health. 2011;39(7 Suppl):30–3.
21. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med
Bull. 1997;44(4):445–8.
22. Schmidt M, Pedersen L, Sorensen HT. The Danish civil registration system as
a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–9.
23. Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H. Introduction to
Danish (nationwide) registers on health and social issues: structure, access,
legislation, and archiving. Scand J Public Health. 2011;39(7 Suppl):12–6.
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke
JP. The strengthening the reporting of observational studies in
epidemiology (STROBE) statement: guidelines for reporting observational
studies. J Clin Epidemiol. 2008;61(4):344–9.
25. Schmidt M, Maeng M, Madsen M, Sorensen HT, Jensen LO, Jakobsen CJ.
The Western Denmark heart registry: its influence on cardiovascular patient
care. J Am Coll Cardiol. 2018;71(11):1259–72.
26. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The
predictive value of ICD-10 diagnostic coding used to assess Charlson
comorbidity index conditions in the population-based Danish National
Registry of patients. BMC Med Res Methodol. 2011;11:83.
27. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al.
ACC/AHA 2005 PRACTICE Guidelines for the management of patients with
peripheral arterial disease (lower extremity, renal, mesenteric, and
abdominal aortic): a collaborative report from the American Association for
Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular
Angiography and Interventions, Society for Vascular Medicine and Biology,
Society of Interventional Radiology, and the ACC/AHA Task Force on
Practice Guidelines (Writing Committee to Develop Guidelines for the
Management of Patients With Peripheral Arterial Disease): endorsed by the
American Association of Cardiovascular and Pulmonary Rehabilitation;
National Heart, Lung, and Blood Institute; Society for Vascular Nursing;
TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.
Circulation. 2006;113(11):e463–654.
28. Rhee SY, Kim YS. Peripheral arterial disease in patients with type 2 diabetes
mellitus. Diabetes Metab J. 2015;39(4):283–90.
29. Cornejo Del Rio V, Mostaza J, Lahoz C, Sanchez-Arroyo V, Sabin C, Lopez S,
et al. Prevalence of peripheral artery disease (PAD) and factors associated: an
epidemiological analysis from the population-based screening PRE-diabetes
and type 2 DIAbetes (SPREDIA-2) study. PLoS One. 2017;12(10):e0186220.
30. Gurney JK, Stanley J, York S, Rosenbaum D, Sarfati D. Risk of lower limb
amputation in a national prevalent cohort of patients with diabetes.
Diabetologia. 2018;61(3):626–35.
31. Agarwal AK, Singh M, Arya V, Garg U, Singh VP, Jain V. Prevalence of peripheral
arterial disease in type 2 diabetes mellitus and its correlation with coronary
artery disease and its risk factors. J Assoc Physicians India. 2012;60:28–32.
32. Sarangi S, Srikant B, Rao DV, Joshi L, Usha G. Correlation between peripheral
arterial disease and coronary artery disease using ankle brachial index-a
study in Indian population. Indian Heart J. 2012;64(1):2–6.
33. Available from: http://www.sst.dk/~/media/DBA260D59A054685A46916
97D622C7D1.ashx.
Kamil et al. BMC Cardiovascular Disorders          (2019) 19:234 Page 8 of 9
34. Sardu C, Barbieri M, Balestrieri ML, Siniscalchi M, Paolisso P, Calabro P, et al.
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction
(STEMI) patients: clinical outcomes at 1-year follow-up. Cardiovasc Diabetol.
2018;17(1):152.
35. Landsberg L, Molitch M. Diabetes and hypertension: pathogenesis,
prevention and treatment. Clin Exp Hypertens (New York, NY : 1993).
2004;26(7–8):621–8.
36. Balestrieri ML, Rizzo MR, Barbieri M, Paolisso P, D'Onofrio N, Giovane A, et al.
Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic
plaques: effects of incretin treatment. Diabetes. 2015;64(4):1395–406.
37. Vrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M. Impact of
diabetes on mortality in peripheral artery disease: a meta-analysis. Clin
Cardiol. 2017;40(5):287–91.
38. Freisinger E, Malyar NM, Reinecke H, Lawall H. Impact of diabetes on
outcome in critical limb ischemia with tissue loss: a large-scaled routine
data analysis. Cardiovasc Diabetol. 2017;16(1):41.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kamil et al. BMC Cardiovascular Disorders          (2019) 19:234 Page 9 of 9
